- Top 9 Drugs With the Biggest Price Increases Over 2 Years (pharmacytimes.com)
Nine widely-used medications have experienced substantial price surges over the past 2 years, adding $5.1 billion to overall drug spending during this time period...7 of these 9 drugs were found by the Institute of Clinical and Economic Review (ICER) to be lacking sufficient clinical evidence to support such price increases. Not only did adalimumab top the list of best-selling drugs last year, but the anti-inflammatory medication ranked first in terms of the most substantial price hikes from 2016 to 2018...READ MORE
- This Week in Managed Care: October 11, 2019 (ajmc.com)
Laura Joszt, Managing Editor at The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network
- This Week in Managed Care: October 4, 2019 (ajmc.com)
Laura Joszt, Managing Editor at The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network
- Endo comes out on top in its fight with FDA and bulk compounder (fiercepharma.com)
...Endo International...has prevailed in its two-front fight with the FDA and bulk compounders. The resolution has ended competition for its vessel constrictor Vasostrict...The drugmaker...has dropped its litigation against the FDA...the FDA amended its draft guidelines to stop compounders from making vasopressin...While the ruling is specific to vasopressin, it is believed to have precedent for other drugmakers whose drugs are targeted by large-scale compounders for generic competition...READ MORE
- October 18 Pharmacy Week in Review (pharmacytimes.com)
Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
- October 11 Pharmacy Week in Review (pharmacytimes.com)
Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
- October 4 Pharmacy Week in Review (pharmacytimes.com)
Nicole Grassano, PTNN, Pharmacy Week in Review, this weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
- This Week in Managed Care: October 18, 2019 (ajmc.com)
Laura Joszt, Managing Editor at The American Journal of Managed Care. Welcome to This Week in Managed Care from the Managed Markets News Network
- California To Make HIV Prevention Drugs Available Without A Prescription (kunr.org)
California Gov. Gavin Newsom signed a bill...that will make HIV-prevention drugs available without a prescription. It allows pharmacists to dispense both PrEP, or preexposure prophylaxis, and PEP, post-exposure prophylaxis...The legislation also prohibits insurance companies from requiring patients to obtain prior authorization before using their benefits to obtaining the medications...The law requires pharmacists to provide instruction on using the prophylaxis, as well as its possible side effects...READ MORE
- 340B allies rally Congress to ensure Pelosi drug price plan doesn’t imperil discounts (fiercehealthcare.com)
A 340B advocacy group is imploring congressional allies to ensure House Speaker Nancy Pelosi’s drug prices plan won’t prevent hospitals from getting discounts under the program...The hospital industry-backed advocacy group 340B Health sent a letter to the House Energy & Commerce Committee...extolling the virtues of the program. The letter comes after the release of Pelosi’s Lower Drug Costs Act, which would call for the Department of Health and Human Services secretary to select at least 25 drugs a year to negotiate for a lower price...Currently, the legislative text says that for each year that a negotiated price is applied that drug shall “not be considered a covered outpatient drug subject to an agreement under … 340B.”...READ MORE